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Cerebral palsy due to perinatal injury to cerebral whitematter is usually not caused by geneticmutations, but by ischemia and/or inﬂam-
mation. Here, we describe an autosomal-recessive type of tetraplegic cerebral palsy with mental retardation, reduction of cerebral white
matter, and atrophy of the cerebellum in an inbred sibship. The phenotype was recorded and evolution followed for over 20 years. Brain
lesions were studied by diffusion tensor MR tractography.
Homozygosity mapping with SNPs was performed for identiﬁcation of the chromosomal locus for the disease. In the 14 Mb candidate
region on chromosome 7q22, RNA expression proﬁling was used for selecting among the 203 genes in the area. In postmortem brain
tissue available from one patient, histology and immunohistochemistry were performed. Disease course and imaging were mostly remi-
niscent of hypoxic-ischemic tetraplegic cerebral palsy, with neuroaxonal degeneration and white matter loss. In all ﬁve patients, a donor
splice site pathogenic mutation in intron 14 of the AP4M1 gene (c.1137þ1G/T), was identiﬁed. AP4M1, encoding for the m subunit
of the adaptor protein complex-4, is involved in intracellular trafﬁcking of glutamate receptors. Aberrant GluRd2 glutamate receptor
localization and dendritic spine morphology were observed in the postmortem brain specimen. This disease entity, which we refer to
as congenital spastic tetraplegia (CST), is therefore a genetic model for congenital cerebral palsy with evidence for neuroaxonal damage
and glutamate receptor abnormality, mimicking perinatally acquired hypoxic-ischemic white matter injury.Introduction
Tetraplegic cerebral palsy (CP) can be caused by global
hypoxia-ischemia of the brain in (near) term newborns
and is often associated with neonatal encephalopathy.1,2
In large collaborative studies, this type of CP represents
18%of all cases.3 Primarywhitematter injury is uncommon
in this context. The classical symptoms are four-limb spas-
ticity (quadriplegia) with abnormal muscular tone, spasms,
involuntary movements, and muscle wasting. This type of
CP is usually associated with moderate to severe learning
disabilities, abnormalities of speech and vision, and
epilepsy in50%of the cases.1–3 Periventricularwhitematter
injury (PVWMI) is often seen in pretermnewborns affected
by CP.2,4 PVWMI is diffuse and the culprit is the immature
oligodendrocyte at ~30 weeks of gestation. Histopatholog-
ical consequences are periventricular leukomalacia (focal
or widespread gliotic and/or cystic lesions) and hypomyeli-
nation.4,5 Associated neuroaxonal degeneration and loss of
subplate neurons correlate with cortical and long trait
degeneration on brain imaging and contribute to visual,
motor, and cognitive problems.6–8 It is under debate
whether the neuronal loss precedes or follows myelin loss,
but the two events could be concomitant.40 The American Journal of Human Genetics 85, 40–52, July 10, 200PVWMI is thought to result from an excessive release
of glutamate, free radicals, thrombotic factors, and inﬂam-
matory cytokines. Genetic predisposition may play a
role.2,9 Different glutamate receptors have been implicated
in increased calcium inﬂux, which mediates glutamate
excitotoxicity, including mainly a-amino-3-hydroxy-5-
methyl-4-isoxazolepropionic acid (AMPA) and kainate
type receptors.10–13 AMPA receptors are highly expressed
in migrating interneurons and in immature oligodendro-
cytes at the time when they initiate myelination, and
this might make them vulnerable to ischemic glutamate
release and intracellular Ca2þoverload.14 Increased recy-
cling and switch in receptor subunit composition is
observed in hypoxia-ischemia models.12,13
Glutamate receptors are selectively transported to the
synaptic membrane by vesicular trafﬁcking, under control
of proteins such as TARPs and the adaptor protein (AP)
complexes.12,15,16 AP complexes form a major component
of the vesicle coat machinery and such as a component
mediates trafﬁcking between the trans-Golgi network
(TGN), endosomes, and the plasma membrane.17,18 Four
different protein complexes, AP-1 to AP-4, have been
described, each with a typical heterotetrameric structure
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subunit. Disruption of AP-4 complex integrity in knockout
mice lacking the AP-4 beta subunit (MIM 607245) leads to
mislocalization of AMPA glutamate receptors in the cere-
bellum.16 Until now, no human disorder has been associ-
ated with mutations of the AP-4 complex subunits.19
Here, we identify a mutation in the AP4M1 gene (MIM
602296), encoding the m subunit of the adaptor protein
complex-4, as the cause of an autosomal-recessive disease
presenting as tetraplegic cerebral palsy with mental retar-
dation and evidence for glutamate-related neuronal
dysfunction.
Material and Methods
Written informed consent was obtained from patients and rela-
tives.
Fibroblast Cell Culture and RNA Isolation
Skin ﬁbroblasts from patients and controls were cultured in 175
cm2 culture ﬂasks in Dulbecco’s modiﬁed Eagle medium
(DMEM) until 80% conﬂuence. Total RNA was extracted with Tri-
zol reagent (GIBCO BRL Life Technologies, Gaithersburg, MD,
USA) and puriﬁed with QIAGEN RNeasy mini columns (QIAGEN,
Valencia, CA, USA) according to manufacturers’ protocols.
DNA Isolation
DNA was isolated from blood samples with the PUREGENE
Genomic DNA Isolation Kit (Gentra).
Genotyping
SNP Array Analysis
SNP genotypes were obtained in accordance with the Affymetrix
(Santa Clara, CA, USA) standard protocol for the GeneChip
mapping 100K Xba and Hind arrays.
In brief, 250 ng of total genomic DNA was digested with either
HindIII or XbaI. Appropriate adaptors were ligated to the four
base-pair overhang of the DNA fragments. A single primer was
used for ampliﬁcation and PCR products were puriﬁed. After frag-
mentation with DNase I, products were labeled with biotin and
hybridized to the array. The arrays were washed and stained with
streptavidin-phycoerythrin in the Affymetrix ﬂuidics station 450
and scanned in the GeneChip Scanner 3000 G7. The images of
the scans were collected and intensities weremeasured in the Affy-
metrix GeneChip operating Software (GCOS). Genotype data anal-
ysis was performed in Affymetrix GeneChip Genotyping analysis
software (GTYPE) with the Dynamic Model algorithm (DM).
Microsatellite Markers
Homozygosity of the region on chromosome 7q22 was conﬁrmed
by use of twomicrosatellite markers (D7S657and D7S515) selected
from the ABI prism set MD 10 (version 2.5) and a number of
markers selected from the Marshﬁeld map, with primers newly
selected. Primers in the NRCAM gene were newly developed.
Primers used are indicated in Table S1 available online.
Markers were ampliﬁed with 50 ng genomic DNA in 11 ml PCR
reactions containing 13 PCR rxn buffer (Invitrogen), 1.4 mM
MgCl2, 0.18 mM of each dNTPs, 0.01 mM FW primer, 0.5 mM RV
primer, 0.5 mMM13 tail (either FAM, VIC or NED), and 0.04 U plat-
inum Taq (Invitrogen). Ampliﬁcation conditions were 50 at 94C
followed by 35 cycles of 3000 at 94C; 3000 at 55C; and 3000 atTh72C; with a ﬁnal extension for 100 at 72C. PCR products were
pooled in panels and loaded on an ABI 3100 automated sequencer.
Data were analyzed with Gene Mapper Version 2.1 software
(Applied Biosystems).
Linkage Analysis
CSV ﬁles containing SNP call data and pedigree data were con-
verted by affy2mega to ﬁles that were compatible for calculating
LOD scores with Allegro.20 Mendelian inheritance check was
performed for all family members, with the program PedCheck.21
SNPs showing Mendelian inconsistencies were excluded from the
calculations. SNP allele frequencies were used from the Affymetrix
100K annotation ﬁle. SNPs with a minor allele frequency smaller
than 0.01 as well as SNPs with a call rate lower than 95% were
excluded from the calculations. Multipoint linkage analysis was
performed with Allegro with a SNP spacing of 0.3 cM. LOD scores
were calculated with the assumption that the disease was an auto-
somal-recessive disorder with 99% penetrance. The linkage anal-
ysis was performed including the consanguinity loop; individual
III-3 was not included in the linkage study because of insufﬁcient
computer memory.
Haplotypes with CA repeats were constructed manually, on the
basis of the minimal number of recombinations. Gene data were
obtained from the NCBI Genome Browser build 36.3.
Expression Array Analysis
GeneChips (HG U133 Plus 2.0) were purchased from Affymetrix.
Target preparation and microarray processing were carried out
according to the manufacturer’s recommendations.
In brief, 5 mg of total RNA was used for double-stranded cDNA
preparation. Biotinylated cRNAwas synthesizedwith an RNA tran-
script labeling kit and 20 mg of the cRNA product was chemically
fragmented to ~50–200 nucleotides. The fragmented cRNA was
hybridized to an Affymetrix HG U133 Plus 2.0 chip. Chips were
washedandstainedwith theEukGE-WS2v5protocolonanAffyme-
trix ﬂuidics 450 station. The stain included streptavidin-phycoery-
thrin (10 mg/mL) andbiotinylated goat anti-streptavidin (3 mg/mL).
Fluorescence intensities were captured with an argonion laser
confocal scanner.
Expression Data Analysis
Scanned output ﬁles were analyzed with GeneChip Operating
Software 1.4 (GCOS; Affymetrix). For examining the quality of
the arrays, the R function AffyQC was run on the CEL ﬁles.
Data was normalized in R programwith RMA (Robust Multichip
Average) normalization. Data analysis was done with Omniviz
software version 5.0.1 (Omniviz, Biowisdom, Maynard, MA,
USA). Only the genes (¼357 Probe Set Ids, according to Affymetrix
annotation ﬁle: HG-U133_Plus_2.na25.annot) from the linkage
region were selected for further (supervised) analysis. Differen-
tially expressed genes between patients and controls were identi-
ﬁed with statistical analysis of microarrays (SAM analysis). For
obtaining the level of differences in expression, log2 ratios
between patients and controls were calculated as well.
The Affymetrix HG-U133_plus2 arrays contained one probe set
for the AP4M1 gene, consisting of 11 probes, divided over exons
10–15. The percentage of present calls (~45%), background, and
ratio of GAPDH 30 to 50 all indicated a high quality of the samples.
Sequence Analysis
Primers used for sequence analysis are indicated in Table S2.e American Journal of Human Genetics 85, 40–52, July 10, 2009 41
Ampliﬁcation reactions were performed in a total volume of
25 ml, containing 13 PCR buffer (Invitrogen), 1.5 mM MgCl2,
200 mM of each dNTP, 1 mM forward primer, 1 mM reverse primer,
0.1 units Platinum Taq DNA polymerase (Invitrogen), and 25 ng
genomic DNA. PCR conditions: 20 94C, 30 cycles of 3000 94C,
3000 60C, 9000 72C with a ﬁnal extension for 100 72C.
PCR reactions were puriﬁed with ExoSAP-IT (USB). Direct
sequencing of both strands was performed with Big Dye Termi-
nator chemistry ver. 3.1 (Applied Biosystems) as recommended
by the manufacturer.
DNA fragment analysis was performed with capillary electro-
phoresisonanABI3100GeneticAnalyzer (AppliedBiosystems)and
the software package Seqscape (Applied Biosystems, version 2.1).
The nomenclature of the mutation is c.1137þ1G/T, where the
A from translation start ATG from the transcript was taken as 1.
RT-PCR
Reverse transcriptase was performed on 2 mg RNA in a total volume
of 40 ml with the iScript cDNA Synthesis Kit (BioRad) according to
the manufacturer’s instructions.
RT-primers spanningAP4M1exon10–15are indicated inTableS3.
Ampliﬁcation reactions were performed in a total volume of
25 ml, containing 13 PCR buffer (Invitrogen), 1.5 mM MgCl2,
200 mM of each dNTP, 1 mM forward primer, 1 mM reverse primer,
0.1 units Platinum Taq DNA polymerase (Invitrogen), and 1 ml
cDNA. PCR conditions: 20 94C, 30 cycles of 3000 94C, 3000 60C,
9000 72C with a ﬁnal extension for 100 72C.
Real-Time PCR Analysis
Relative quantiﬁcation was performed with real-time PCR anal-
ysis. Reverse transcriptase was performed on 8 mg RNA with the
iScript cDNA Synthesis Kit (BioRad) according to the manufac-
turer’s instructions.
Of each cDNA 0.5 ml was used in a 25 ml reaction with 13 iTaq
SYBR Green Supermix with ROX (Bio-Rad) and 200 nM of each
primer. Real-time PCR was performed on a 7300 Real-Time PCR
System (Applied Biosystems), cycle conditions were 100 95C
initial denaturation, 40 cycles 1500 denaturation, annealing, and
extension and data collection 10 60C.
Data were analyzed with the software package 7300 System SDS
Software RQ Study Application v1.2.3 (Applied Biosystems).
For Q-PCR two primer sets for AP4M1, one primer set for the
housekeeping gene ACTB (Entrez GeneID 60 [MIM 102630]) and
one primer set for the housekeeping gene UBE2D2 (Entrez GeneID
7322 [MIM 602962]) were designed with the Primer Express soft-
ware (Applied Biosystems). For primer sequences, see Table S4.
All reactions were performed in triplets. Relative quantiﬁcation
was calculated with the comparative Ct Method.
Transfection of AP4M1 in Human Embryonic
Kidney HEK293 Cells
Primers to produce control and patient constructs are given in
Table S5.
Ampliﬁcation reactions were performed in a total volume of
25 ml, containing 13 PCR buffer (Invitrogen), 1.5 mM MgCl2,
200 mM of each dNTP, 1 mM forward primer, 1 mM reverse primer,
1 unit Platinum Taq DNA polymerase (Invitrogen), 0.1 U pfu DNA
polymerase (Invitrogen), and 1 ml cDNA. PCR conditions are as
follows: 20 94C, 30 cycles of 3000 94C, 3000 60C, 9000 72C, and
a ﬁnal extension of 100 72C.42 The American Journal of Human Genetics 85, 40–52, July 10, 200Cloning of PCR products in pcDNA3.1_V5 His TOPO (Invitro-
gen) was performed according to the standard protocol.
The pcDNA3.1_V5 His_AP4M1 patient and control constructs
were cotransfected with pcDNA3.1_V5 His_TSC2 in HEK293 cells
with PEI (polyethylenimine) transfection.
A total of 1 mg DNA was diluted in 125 ml Dulbecco’s modiﬁed
Eagle medium (DMEM) containing 3 mg polyethyleneimine (Poly-
sciences, Eppelheim, Germany).
After 15 min incubation at room temperature the DNA-poly-
ethyleneimine complexes were added to the HEK293 cells in
35 mm diameter dishes (80% conﬂuent). After 4 hr at 37C, the
transfection mixture was replaced with DMEM containing 10%
fetal calf serum. Twenty-four hours after transfection, the expres-
sion of AP4M1_ctrl, AP4M1_pat and TSC2 (MIM 191092) were
determined by immunoblotting. Antibodies, vector, and con-
structs used are V5 antibody obtained from Invitrogen,
AP4M1_lupin antibody (courtesy of M.S. Robinson and J. Hirst),
and TSC2 construct in pcDNA3.1 vector, courtesy of Mark Nellist,
ErasmusMC, Rotterdam.22
SDS PAGE and Western Blot
Transfected HEK293 cells were homogenized in PBS with protease
inhibitors (protease inhibitor cocktail mix complete, Roche), 1/6
v/v of homogenate was boiled in SDS-loading buffer and run on
a 12% SDS-polyacrylamide gel and electroblotted onto nitrocellu-
lose. The V5-tagged constructs were detected with mouse a-V5
(Invitrogen) and the AP4M1 constructs were detected with rabbit
a-AP4M1 (courtesy of M. Robinson and J. Hirst) as the primary
antibody. Horseradish peroxidase (HRP)-labeled anti-mouse and
anti-rabbit Ig serum was used as secondary antibody, thereby
allowing chemiluminescence detection with ECL (Amersham).
AP4M1 mRNA In Situ Hybridization
on Mouse Sections
Wild-typemouse embryos (FVB/n) were used in preparing sections
for the mRNA in situ hybridization experiments. Pregnant mice
were killed by cervical dislocation and embryos were isolated in
PBS on ice.Whole heads (E12.5, E14.5, and E16.5) or isolated brain
(E18.5, P4) were snap frozen on dry ice and stored at 80C until
sectioning. Noon on the date of the vaginal plug was deﬁned as
E0.5. Housing and breeding were performed with standard condi-
tions. The animal experiments were approved by the ethical
commission for animals (Erasmus MC OZP 140-07-03).
Whole head or brain was sectioned sagittally and coronally at
12 mm with a Jung CM300 cryostat (Leica).
Probe Preparation
A DIG-UTP labeled mRNA probe, encompassing nt 1037 bp of the
AP4M1 gene (primers used: 50-AATGAGGGAACCATCTCACG-30
[forward] and 50-TTGCTGTGGCTTAGATGTCG-30 [reverse]), was
generated with T7 (antisense) and SP6 (sense) RNA polymerase
(Roche), according to the suppliers’ protocol. The mRNA in situ
hybridization was performed according to Wilkinson.23 Stained
sections were scanned by the NanoZoomer Digital Pathology
System (Hamamatsu).
DTI Fiber Tracking
All imaging was performed on a 1.5-T GE EchoSpeed scanner (GE
Medical Systems, Milwaukee, WI, USA). For DTI, an echoplanar
sequence with diffusion gradients (b ¼ 1000 s/mm2) applied in
25 noncollinear directions was used. Diffusion tensor images
were transferred to a GE Advantage Windows workstation9
Table 1. Clinical Neurological Presentation
Patient IV-1 IV-3 IV-4 IV-5a IV-6
Age of onset infancy infancy infancy infancy infancy
Age at observation
(years)
24 23 22 1.5a 21
Head circumference 1 SD 0 SD 2 SD ? 2.5 SD
Mental retardation þþþ þþþ þþþ þþþ þþþ
General tone at onset low low low low low
Contractures adducted thumbs,
clubfoot
adducted thumbs adducted thumbs adducted thumbs,
clubfeet
no
Pseudobulbar signs
(speciﬁed)
drooling, stereotypic
laughter, jaw jerk þþ,
gag reﬂex þþ
drooling, stereotypic
laughter, jaw jerk þþ,
gag reﬂex þþ
drooling, stereotypic
laughter, tongue
thrusting, jaw jerk þþ,
gag reﬂex þþ
?a stereotypic laughter,
jaw jerk þþ, gag
reﬂex þþ
Speech never acquired never acquired never acquired never acquired dysarthric
monosyllables
Sphincter control absent absent absent absenta absent
Corticospinal
involvement
limb hypertonia;
>DTR; extensor plantar
reﬂex
limb hypertonia;
>DTR; extensor
plantar reﬂex
limb hypertonia;
>DTR; extensor plantar
reﬂex
?a limb hypertonia;
>DTR; extensor
plantar reﬂex
Deambulation never achieved never achieved never achieved never achieved never achieved
Purposeful hand use no no No noa Reaches for objects
Loss of acquired
function
standing with support
at age 6 years
no No ?a standing at age
7 years
Brain imaging normal CT (at age
3 months)
MRI: Abn. WM, wide
ventricles, cerebellar
atrophy
MRI: Abn. WM, wide
ventricles, normal
cerebellum
n.d. MRI: Abn. WM,
wide ventricles,
cerebellar atrophy
VEP normal delayed bilaterally normal normal normal
Eye examination n.d. normal n.d. n.d. pale optic disks
The following symbol and abbreviations are used: ?, unknown. n.d., not determined; WM, white matter; SD, standard deviation; >DTR, high deep tendon
reflexes; Abn, Abnormal; and MRI, magnetic resonance imaging.
a Patient died at the age of 17 months.(General Electric Medical Systems, Milwaukee, WI, USA) for post-
processing with Functool 2000 software (General Electric). DTI
measurements were taken from regions of interest (ROIs) posi-
tioned bilaterally within individual white matter tracts. For the
placement, we used standard-size, round-shaped 30 pixel ROIs.
The ROIs were used as seed points to perform ﬁber tracking
(minimum anisotropy threshold 0.18).
Immunohistochemistry
Limited parafﬁn embedded brain autopsy material from patient
IV-5 (age 17 months) and an aged matched control of 18 months
was available of cerebral cortex and cerebellum.
Immunohistochemistry with antibodies directed against
GluRd2 (glutamate receptor delta 2) (MIM 602368), Calbindin
(MIM 114050), and AP4M1 was performed in accordance with
standard protocols. In brief, sections were deparafﬁnized, antigen
retrieval was done with pressure-cooking in 0.1M sodium citrate
buffer (pH 6) for 5 min, and endogenous peroxidase activity was
inhibited by 30 min incubation in PBS-hydrogen peroxide
(0.6%)-sodium azide solution (0.125%).
Subsequently, sections were immunoincubated with the
primary antibody for 16 hr at 4C. The Histostain-Plus broad-spec-
trum kit DAB (Zymed, San Francisco, CA, USA) was used as a detec-Thtion system. Slides were counterstained with Mayer’s Haematoxy-
lin and mounted in Entellan.
Antibodies used were Go-anti-GluRd2 (Grid2; Santa Cruz
sc-26118) and Ra-anti-Calbindin (Chemicon AB1778).
Results
Phenotype of the CST Syndrome
Family History
Clinical information of the patients with a cerebral palsy-
like disease, which we deﬁne as congenital spastic tetraple-
gia (CST), has been collected in a clinical follow-up of
20 years and is summarized in Table 1. The patients belong
to a sibship of 11 children from consanguineousMoroccan
parents (Figure 1). Seven patients are affected by arterial
tortuosity syndrome (ATS [MIM 208050]) (indicated with
an asterisk in Figure 1), caused by a homozygous nonsense
mutation in the SLC2A10 gene on chromosome 20q.24
Five siblings from this family (patients IV-1, IV-3, IV-4,
IV-5, and IV-6), further referred in the paper as the ‘‘pro-
bands,’’ suffer from a separate neurological disorder, note American Journal of Human Genetics 85, 40–52, July 10, 2009 43
segregatingwithATS.Of theseﬁvepatients, onewashetero-
zygote for the SLC2A10 (MIM 606145) mutation and has
no ATS symptoms (patient IV-6),24 whereas the other four
have both ATS and the neurological disorder. ATS patients
in general24,25 and ATS patients from this family (IV-2, IV-
9, and IV-10) have no neurological symptomatology, sug-
gesting that the neurological disorder in this family segre-
gates as a trait distinct from ATS. Some ATS patients have
been reported with enlarged head circumference.26 On
the basis of a sibship of ﬁve affected probands of different
sex and consanguinity of healthy parents, we assumed the
neurologic disorder to be autosomal recessive.
Disease Phenotype
Prenatal ultrasound of patient IV-6 pregnancy showed
ventricle dilatation in the 20th week. All ﬁve probands pre-
sented postnatally with early infantile hypotonia, delayed
psychomotor development, strabismus, lack of indepen-
dent walking, and severe mental retardation (total IQ 20,
DSM-IV code 318.2).27 Progressive spasticity of all limbs
Figure 1. Pedigree and Haplotypes Linkage Region
Pedigree of the family with four generations (I–IV). Five siblings in
generation IV (IV-1, IV-3, IV-4, IV-5, and IV-6) are affected by CST
(ﬁlled symbols). Empty symbols represent those unaffected for
CST; the asterisk represents those affected with arterial tortu-
osity syndrome.24 Haplotypes with chromosome 7 microsatellite
markers are indicated. The assumed affected haplotype is indi-
cated in gray. Recombination events delineating the region of
homozygosity in the probands are indicated with a horizontal
line. The proximal boundary is determined by a recombination
event in individual IV-6 between D7S657 and D7S1820. A histor-
ical recombination event that was already present in both parents
between markers D7S2420 and D7S496 delimits the distal border.
‘‘/’’ indicates the location of the AP4M1 gene.44 The American Journal of Human Genetics 85, 40–52, July 10, 200with generalized hypertonia, high deep tendon reﬂexes,
and Babinski signs were present by the end of the ﬁrst
year. Speech was absent or limited to a few meaningful
but dysarthric monosyllables. Pseudobulbar signs such as
drooling, stereotypic laughter, and exaggerated jaw jerk
were present in all patients. They never experienced
seizures. There were no clinical signs of cerebellar ataxia,
although spasticity prevented adequate testing. Disease
course was slowly progressive with minimal or no regres-
sion in 20 years. One patient (IV-5) died at 17 months of
aspiration pneumonia (Table 1).
Patients and Clinical Investigation
Patient IV-1 has ATS. Postnatally she showed micro-
cephaly, hypotonia, strabismus, and thumb adduction.
At the age of 6 years she could stand with support, but
this was lost later on; she never developed understandable
speech and suffered from deep mental retardation. Neuro-
logical and metabolic investigations at that age were
normal, including brain CT, muscle biopsy, skin EM,
EEG, EMG, VEP, and BAER. At age 16, she was wheelchair
bound with spastic tetraparesis, adducted thumbs with
tenar hypoplasia, and kyphosis; she made eye contact
notwithstanding the squint, was able to sit unsupported,
drooled, presented with bursts of stereotypic laughter,
and showed ﬁxed contractures of large joints (Table 1).
She chews and swallows normally. Acrocyanosis and skin
laxity were considered features of ATS.
Patient IV-3 has ATS and was born with bilateral club-
foot. He is at the moment the most severely affected,
and his psychomotor development was never higher
than 6 months’ level. He never achieved deambulation,
unsupported sitting, or speech. From infancy, convergent
bilateral strabismus was present, and this condition didn’t
improve after surgeries. Examination at age 22 showed
normal head circumference, spastic tetraparesis with
remarkable hypertonia impairing wheelchair use, tenar
hypoplasia and thumb adduction, scoliosis, drooling,
and strabismus; however, he chews and swallows. He
makes no contact but can laugh stereotypically and has
no day-night rhythm. A brain CT scan at the age of
4 months reported wide ventricles and subarachnoid
spaces. A brain MRI at the age of 15 years showed diffuse
cerebellar atrophy, asymmetrically enlarged lateral ventri-
cles, thin corpus callosum, and normal signal intensity of
residual white matter (Figure 2A). MR angiography de-
tected intracerebral vessel tortuosity.
Patient IV-4 has ATS. At birth her head circumference
was at 2 SD and she was hypotonic. She suffered from
deep mental retardation, never learned to speak or walk,
but can sit on her knees. Spastic paraparesis required hip
surgery. At the age of 22, she is borderline microcephalic
and passive, and she sometimes articulates monosyllables
and shows mouth dyskinesia, tongue thrusting, and bursts
of unprovoked laughter. EEG, EMG, and VEP ﬁndings at
the age of 11 years were unremarkable (Table 1). Brain
MRI at the age of 15 years showed enlarged lateral ventri-
cles, white matter loss without hyperintensity on T29
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Figure 2. Brain Magnetic Resonance Imaging and DTI
(A) T2 weighted brain MRI of patient IV-3 at the age of 15 years
shows enlarged and asymmetric lateral ventricles, thin corpus cal-
losum, white matter loss, with normal signal intensity, thickened
skull (left), diffuse cerebellar atrophy, wide IVth ventricle, and
hypoplastic pons and vermis (center). Magnetic resonance angiog-
raphy (MRA) shows intra- and extracranial tortuosity of the large
vessels (right), in light of the fact that this proband is also affected
by ATS.
(B) T2 weighted brain MRI of patient IV-4 at the age of 14 years
shows enlarged lateral ventricles, particularly in the occipital
area, with irregular contour and white matter loss with normal
intensity and wide IVth ventricle (left and center). MRA shows
arterial tortuosity of the neck and intracerebral vessels, related to
ATS (right).
(C) Conventional MRI of patient IV-6, performed at the age of
13 years, shows on T2 weighted images (ﬁrst and second from
left) diffuse but asymmetric white matter loss with massive
enlargement of the occipital horns. Stretched gyri and asymmetry
of the thalami suggest hydrocephalus in the past (ﬁrst left and
second from right). Signal intensity of the residual white matterThweighted images, normal cerebellum, and tortuosity of the
neck and cerebral vessels at MR angiography (Figure 2B).
Patient IV-5hadATSandwas thedizygotic twinofpatient
IV-6. At birth in the 38th gestational week, he presented
with hypotonia, normal head size, low Apgars, and club-
feet. Slidingdiaphragmatichernia andgastro esophageal re-
ﬂux were later diagnosed. After gastric fundoplication sur-
gery, he developed aspiration pneumonia and died at the
age of 17 months. Autopsy revealed diffuse brain atrophy
and signsof arterial tortuosity in all organs.25HisCNSmate-
rial was revised (see brain pathology ﬁndings).
Patient IV-6 is the only patientwithout ATS (he is a carrier
for this disease and heterozygous for the familial W170X
SLC2A10 mutation). He is the dizygotic twin of patient
IV-5. During pregnancy, prenatal ultrasound raised suspi-
cion of hydrocephalus and porencephalic cystic enlarge-
ment of the left occipital ventricle. At birth, Apgars were
normal, head circumference was at 2SD, and his weight
was at 0 SD. First examination at the age of 1 year revealed
psychomotor retardation. He became hypertonic, under-
went Achilles tendon surgery, and learned to stand at the
age of 7 years, but this was lost later on. He shows conver-
gent strabismus (recidivating after surgery) but makes eye
contact. He could speak meaningful but dysarthric words
with echolalia and use a spoon at the age of 15 years, but
at the age of 21 he speaks monosyllables and can accom-
plish simple manual tasks such as reaching for objects. He
can shufﬂe on his knees and sit unsupported. Neurological
examination shows mental retardation, spastic tetraplegia,
no clear ataxia, normal pain sensation, microcephaly,
drooling, and bursts of unprovoked laughter. Eye fundus
shows pale optic disks. Results of neurological investigation
are summarized in Table 1.
Brain MRI and Diffusion Tensor Imaging
Brain MR imaging and angiography were performed in
probands IV-3, IV-4, and IV-6 (Figures 2A–2C). These
showed consistent anatomical abnormalities in all patients
is normal. No vascular tortuosity at the angiography (right),
conform to heterozygosity for ATS. Mild cerebellar atrophy is
present in T1 sagittal images (second from right).
(D) Repeat MRI at age 21 years of patient IV-6 showing similar
abnormalities with only minimal progression of cerebellar
atrophy.
(E) DTI brain images of the patient (right panel) and age- and sex-
matched control (left panel). Top images show color maps: color
maps are based on major eigenvector orientation in each of the
voxels with red representing right to left, green antero-posterior,
and blue supero-inferior anatomical directions.28 Middle images
show fractional anisotropy maps with an example of regions of
interest (ROIs, round-shaped, 30 pixels) placed in the posterior
limb of the internal capsule (PLIC) (circles). For isotropic diffusion,
FA is zero (no anisotropy ¼ blue). If there is a strongly preferred
direction of diffusion (indicating capture of white matter tracts
in the ROI), FA approaches a value of 1 (red). Bottom images
show ﬁber track images of the corticospinal tract with ROIs as
seedpoints (minimum anisotropy threshold 0.18). Mapping the
directional principal eigenvectors forms the basis for tractography
with the assumption that the principal eigenvector is aligned with
the direction of the ﬁber bundle.28e American Journal of Human Genetics 85, 40–52, July 10, 2009 45
with variable loss of white matter and cerebellar atrophy.
Longitudinal follow-up of proband IV-6 at the age of 13
and 21 years showed unchanged abnormalities. The
residual cerebral and cerebellar white matter showed
normal signal intensity even at follow-up without signs
of demyelination (Figure 2D), suggesting an early develop-
mental defect rather than progressive neurodegeneration.
Brain imaging of patient IV-2 and IV-9 with ATS only was
normal, except for tortuosity of arteries (not shown).
We performed diffusion tensor imaging (DTI) with ﬁber
tracking on MRI in proband IV-6 and an age-matched
control to quantify and visualize white matter tracts. MR-
DTI is based on capturing diffusion of water molecules in
different orientations in lipid-rich brain tissue and can be
expressed as fractional anisotropy (FA).28–31 It is the only
available technique allowing in vivo qualitative and quan-
titative visualization of structural brain connections.32
Because DTI is a fairly new technique, extensive control
data is lacking. We therefore decided to test a healthy
age-matched male control under the same imaging and
analysis conditions.33–35 Postprocessing analysis showed
Table 2. FA Values of DTI for Control and Patient
Control PLIC ALIC CC Genu EC
FA 0.66 0.54 0.77 0.36
L1 11.85 11.8 17 9.82
L2 4.11 5.31 4.01 6.68
L3 2.75 3.89 2.78 4.52
L2þL3/2 3.43 4.60 3.39 5.6
Patient PLIC ALIC CC Genu EC
FA 0.46 0.37 0.42 0.17
L1 10.4 10.04 16.6 8.09
L2 5.05 5.99 9.02 6.61
L3 4.24 4.79 7.45 5.71
L2þL3/2 4.65 5.37 8.24 6.16
Mean values are shown of different DTI indices in (30 pixel size) regions of
interest (ROIs) placed in the posterior limb of the internal capsule (PLIC), the
anterior limb of the internal capsule (ALIC), the genu of the corpus callosum
(CC), and the external capsule (EC).
‘‘FA’’ stands for fractional anisotropy. FA values of 1 indicate high diffusion
anisotropy, in which water diffusion is restricted to one main direction. FA
values close to 0 indicate that the diffusion within the tissue is isotropic.55
L1–L3 refers to values of the eigenvectors. The eigenvalues of the diffusion
tensor are the diffusion coefficients in the three principal directions of diffu-
sivity. Lambda 1 (L1) is the principal eigenvector; it defines the main direction
of diffusion of water molecules. Lambda 2 (L2) is the middle eigenvalue and
lambda 3 (L3) the smallest eigenvalue. Directional diffusivities derived from
DTI measurements can be separated into components parallel (l 1) and
perpendicular (l2 and l3) to the white matter tract. These components are
referred to as the axial diffusivity (lk), and radial diffusivity (lt ¼ (l2 þ l3)/2),
respectively.
The values for FA were low in the white matter tracts of the patient. A signifi-
cant difference between patient and control for both axial (along the axon)
and radial (perpendicular to the axon direction) diffusivity values were found,
with reduced axial and increased radial diffusivity. Decrease in axial diffusivity
(type 2 anisotropy loss) has been associated with axonal pathology, while
increase in transverse (short axes) diffusivity (type 1 anisotropy loss) correlates
with myelin damage.56,5746 The American Journal of Human Genetics 85, 40–52, July 10, 200clear differences in the anisotropy indexes of the white
matter tracts between patient and control, particularly in
corpus callosum, internal and external capsule, indicating
major white matter loss (Figure 2E). FA is believed to reﬂect
many factors including axonal density, integrity, and
degree of myelination.28 Despite the limited reference
data for human age-matched FA, the low FA values in the
patient and pattern of FA changes suggest that the lesions
are related to a combination of axonal disarray and myelin
integrity loss (Table 2).
Molecular Analysis
Linkage and Expression Study
Multipoint linkage analysis on the neurological trait with
100 K SNP array data, including the consanguinity loop,
but without individual III-3, resulted in only one signiﬁ-
cant linkage peak with a maxLOD score of 4.35. The locus
is extending 16.3 cM on chromosome 7q22. (Figure S1).
Haplotype analysis and ﬁne mapping with chromosome
7 polymorphic microsatellite markers conﬁrmed homozy-
gosity in the patients and deﬁned a 14 Mb candidate
region between marker D7S657 to D7S496 (Figure 1), con-
taining 203 genes (NCBI build 36.3).
In order to select putative candidate genes from the
linkage region, we used mRNA expression arrays to study
the transcripts in ﬁbroblasts of probands (IV-1 and IV-3–
IV-6 in Figure 1) and controls (IV-2 and IV-9 plus two inde-
pendent controls). OmniViz supervised clustering and SAM
analysis identiﬁed theAP4M1gene as the strongest downre-
gulated transcript in all neurologically compromised pa-
tients with a 2-fold downregulation of the gene (Figure S2).
Sequence Analysis and Mutation Validation
Sequencing of the AP4M1 candidate locus revealed a splice
donor site homozygous mutation in intron 14,
c.1137þ1G/T, in all ﬁve patients, whereas the parents
were heterozygous (Figure 3A). Given the 100% evolu-
tionary sequence conservation of the þ1G splice donor
site,36 this mutation was expected to destroy the splice
donor site of intron 14. This mutation was not present in
224 ethnically matched Moroccan controls, thereby
making a polymorphism unlikely.37
A transcript of diminished size was observed by RT-PCR
on ﬁbroblast RNA from patients compared to controls,
with primers spanning AP4M1 exons 10–15, suggesting
aberrant splicing in the patients (Figure 3B). Skipping of
exon 14 was conﬁrmed by sequencing the RT-PCR prod-
ucts. Serendipitously, all the AP4M1 probes present on
the Affymetrix HG-U133_plus2 expression arrays are
located at exons 10–15. A number of these probes are on
exon 14, explaining why AP4M1 appeared downregulated.
Relative analysis by quantitative RT-PCR with primer
sets on exons 2–3 showed the presence of equal levels of
mRNA in patients and controls; however, using primer
sets on exons 14–15 showed that in patients, only aberrant
AP4M1 mRNA, lacking exon 14, is synthesized (Figure S3
and Figure 3C). Normal and deduced mutated AP4M1
protein is shown in Figure S4.9
Because AP4M1 protein expression in control ﬁbroblasts
was too low to detect with Western blot analysis, we inves-
tigated the effect of the mutation in cell cultures by ex-
pressing V5-tagged wild-type andmutated AP4M1 (lacking
exon 14) in HEK293 cells and then analyzing them via
immunoblotting. a-V5 as well as a-AP4M1 antibodies
showed thatmutatedAP4M1 induces synthesis of a protein
with a lower molecular weight (44.5 kD), as predicted by
abnormal splicing of exon 14, compared to the expected
normal 50 kD (Figure 3D).
Developmental Expression
Given that CST is compatible with a developmental defect
with onset before birth, timing and localization of the
mouse ortholog Ap4m1 mRNA expression was examined
by in situ hybridization during various stages of mouse
brain development.
Expression of Ap4m1 in all ventricular zones was de-
tected at embryonal stages E12.5, E14.5, E16.5, and E18.5
(Figure 4A). On E16.5, pronounced expression in the upper
layer of the cortical plate is detected, broadening at E18.5
and P4. Additionally, expression was observed in the
lateral and medial ganglionic eminences at E16.5. Cere-
bellar expression was observed at E18.5 and postnatal P4
in the external granular and Purkinje cell (PC) layer, as
well as at P4 also in the internal granular layer. Early
Ap4m1 expression suggests its role in cerebral and cere-
bellar development, and its localization corresponds to
brain areas characterized by neuroglial progenitor prolifer-
ation. This suggests that AP4M1 mutation might affect
neurons as well as oligodendrocytes.
Brain Pathology
Postmortem Brain and Histology
The autopsy brain from proband IV-5, who died of pneu-
monia, weighted 750 g (normal at this age is 1050 g).
Widening of all ventricles and severe thinning of corpus
callosum (Figures S5A–S5C), without signiﬁcant thinning
of the cerebral cortex were consistent with long lasting
reduction of white matter. The cerebral cortex showed a
normal layering without obvious loss of neurons (Fig-
ure S5D). There was marked edema of large parts of the
cortex and basal ganglia, thereby causing a spongiform
appearance. The neurons in these areas were shrunken as
seen in agony hypoxia. The pons was signiﬁcantly atro-
phic whereas the basal ganglia were notmarkedly atrophic.
The fourth ventricle was widened and although the cere-
bellum was not obviously atrophic, there was some thin-
ning of the granular layer (Figure S5C). The dendate
nucleus, however, showed a striking loss and degeneration
of neurons, with slight gliosis (Figure S5E).
Reducedmyelinwithsigniﬁcantgliosis in thewhitematter
of the cerebralhemisphereswasnoticed,with irregular thick-
ening of axons in some long stretches (Figures S6A–S6C). No
signs of active demyelination were visible (Figure S6D). The
number of Purkinje cells in the cerebellumwas not reduced,
but sizes of the cell bodies were slightly reduced and showTha somewhat ovoid appearance (Figures S6E and S6F) as
shown in Figure 4B. This indicates lesions of both neurons
(dentate degeneration, axonal swelling) and glia (reduced
myeling, abnormal gliosis) lineage in the patient brain, but
it does not clarify which event occurred ﬁrst.
Immunohistochemistry
Parafﬁn embedded patient brain material (age 17 months)
has been stored for more than 20 years. Parafﬁn embedded
brain material of an age-matched control (age 18 months)
with a storage time of 10 years was used. Despite a speciﬁc
signal on Western blots, no signal could be observed with
the available AP4M1 antibodies (commercially available as
well as from Robinson & Hirst) in the brain of patient IV-5
and the age-matched control. The AP-4 protein complex is
expressed in the central nervous system neurons and inter-
acts with glutamate receptors 1–4 (GluR1–GluR4 [MIM
138248, 138247, 305915, and 138246]) and glutamate
receptor d2 (GluRd2), which is exclusively expressed in
cerebellar PC.38 However, except for the GluRd2 antibodies
in cerebellum, no immunoreactivity was seen in control
brains with commercial glutumate receptor antibodies
1–4. We proceeded to indirectly test the effect of the
AP4M1mutation by detection and localization of its ligand
GluRd2 on cerebellum parafﬁn sections of patient IV-5 and
two age-matched controls.
PC bodies contain low levels of immunoreactive GluRd2
at all developmental stages.39–41 However, GluRd2 protein
is abundantly expressed on the postsynaptic sites at the
dendritic spines of parallel ﬁber-PC synapses.42–44
In patient IV-5, GluRd2 protein was present in the peri-
karya of the PC and scattered PC bodies with a somewhat
abnormal ovoid shape, as compared to the control (Fig-
ure 4B, upper panel). Yap et al.38 suggested that the AP4
complex interacts with GluRd2 and transports GluRd2 to
the dendrites. The observation ofGluRd2 staining in the PC
perikarya suggests insufﬁcient vesicle-mediated transport
to the dendrite membranes in the patient and receptor
retention in the perinuclear Golgi and endosomal appa-
ratus. In both the patient and the control, punctate signals
were clearly seen in the molecular layer of the cerebellum,
illustrative of synapse-associated signal in dendritic spines.
At higher magniﬁcation, the GluRd2 pattern in the patient
dendrites was coarse, suggesting abnormal and diminished
dendritic arborization of the PC cells.
Immunohistochemical staining with PC-speciﬁc calbin-
din antibodies conﬁrmed coarse spine shape and decreased
dendritic arborization in the patient as compared to the
control (Figure 4B, lower panel).
Both immunohistochemistry and histology are sugges-
tive of primary neuroaxonal abnormalities, concordant
with the in vivo FA data from DTI (Table 2).
Discussion
An integrative bioinformatics approach, combining
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Figure 3. Sequencing and Functional Analysis
(A) Sequence analysis showing the AP4M1mutation in intron 14 (c.1137þ1G/T). The normal sequence from exon 14 to intron 14 is
TTCCAGgtattc, with the last six bases of exon 14 indicated in capital letters and the ﬁrst six bases of intron 14 in lowercase letters. Homo-
zygous normal sequence, homozygous mutation as seen in probands IV-1, -3, -4, -5, and -6, and heterozygous mutation in carriers
(parents III-1,2; sibs IV-2, -7, -8, and -11) are indicated by an arrow.
(B) The left panel shows RT-PCR on ﬁbroblast RNA of patients IV-1, -3, -4, -5, and -6 (P), controls (C), and a heterozygous carrier (H).
Normal product length of 451 bp and reduced product length of 339 bp are indicated. n ¼ negative control without DNA, m ¼ 1 kb
plus marker (Invitrogen). In the right panel is the RT-PCR sequence showing the exon 13 to exon 15 junction fragment, GGTCAGATG
GAC, present in the patients. The arrow indicates the transition from exon 13 to exon 15. Sequence data from patient IV-4 is shown. All
patients showed the same sequence.
(C) qRT-PCR, expression of AP4M1 in ﬁbroblast RNA of control samples (C1-C3, unrelated, plus family member IV-9), patients (IV-1, -3,
-5, and -6), and one heterozygote (IV-2). Values are expressed as x-fold expression relative to expression of the housekeeping gene ACTB,
which is arbitrarily set to 1. Expression of the housekeeping gene UBE2D2 relative to ACTB is used as positive control. Error bars indicate
the standard deviation (n ¼ 3). Expression of UBE2D2 and AP4M1.1 (primers spanning exon 2 and 3) were comparable in all control
samples and patients. AP4M1.3 primers (spanning exon 14–15) showed normalmRNA expression in all control samples, 0.5-fold expres-
sion in the heterozygous family member (IV-2), and a lack of expression on all patients tested. The following abbreviations are used: GG,
normal sequence; GT, heterozygous carrier; and TT, patient with homozygous mutation.48 The American Journal of Human Genetics 85, 40–52, July 10, 2009
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Figure 4. mRNA In Situ Hybridization
and Immunohistochemistry
(A) mRNA ish expression patterns of
Ap4m1 in mouse brain of different devel-
opmental stages (E, embryonal day; p,
postnatal day). Ap4m1 expression is
present in the ventricular zone of all four
brain ventricles on days E12.5, E14.5,
E16.5, and E18.5 (coronal sections, left
and center panels), with expression in the
ventricular zone of the lateral ventricles
more sharply deﬁned. On E16.5, pro-
nounced expression in the upper layer of
the cortical plate is present as well, broad-
ening at E18.5 and P4. Also, expression is
present in de lateral and medial ganglionic
eminences (E16.5). Expression in the
developing cerebellum was observed at
E18.5 and P4 in the external granular and
Purkinje cell layer and at P4 also in the
internal granular layer (E18.5 and P4, right
panel, both images showing sagittal
sections). Control sense probe experiments
were negative (data not shown). The
following abbreviations are used: vz,
ventricular zone; cp, cortical plate; ge,
ganglionic eminence; egl, external gran-
ular layer; igl, internal granular layer; and
pcl, Purkinje cell layer.
(B) Immunohistochemical staining on
brain material from patient IV-5 (17
months) (left) and an age-matched control
(18 months) (right). In the upper panel,
a patient’s cerebellum stained with GluRd2
revealed signal in the perikarya of the PC
cells and slightly abnormally ovoid shaped
perikarya as compared to the age-matched
control. In both patient and controls,
punctuate signals are clearly seen in the
molecular layer of the cerebellum, reﬂect-
ing synapse-associated signaling in dendritic spines. The punctuated GluRd2 pattern is more pronounced in the patient compared to
the control. In the lower panel, staining with PC-speciﬁc calbindin antibodies shows decreased dendritic arborization in the patient
as compared to the control. The following abbreviations are used: gcl, granular cell layer; ml, molecular layer; pc, Purkinje cell body;
and pcd, Purkinje cell dendrites.descent and expression array analysis, enabled us to iden-
tify a recessive AP4M1 gene mutation in this single pedi-
gree. The disease manifests as tetraplegic cerebral palsy;
therefore, we deﬁned it as congenital spastic tetraplegia.
CST has a prenatal onset and is characterized by early
hypotonia changing to spasticity within the ﬁrst year,
quadriplegia, and absence of sphincter control. Spastic tet-
raplegia is associated with lack of speech, strabismus, pseu-
dobulbar signs, clasped thumbs, clubfeet, and severe
mental retardation. Brain MRI shows diffuse loss of peri-
ventricular white matter without signs of demyelination,
thereby leading to ventriculomegaly, hypoplasia of the
corpus callosum, pons, dentate nucleus, vermis, and cere-
bellar atrophy. Quantitative analysis of DTI data indicates
a combination of axonal disarray and loss of myelin integ-rity as expected in PVWMI. Brain pathology in one patient
conﬁrmed cerebral white matter and dentate neuronal
loss, with signs of primary neuroaxonal abnormalities.
Although CST shares signs of hereditary complicated
spastic paraplegia,45 disease course, neuroimaging, and
lack of progressive neurodegeneration46 are reminiscent
of tetraplegic cerebral palsy associated with injury to peri-
ventricular white matter after major hypoxia-ischemia.1,4,8
Age of onset in the hereditary spastic paraplegias is usually
not congenital. Rare early-onset forms have been described
as primary lateral sclerosis (PLS [MIM 606353]), infantile
onset ascending spastic paralysis (IAHSP [MIM 607225]),
and ‘‘complicated’’ hereditary spastic paraplegias
(cSPG).45 Other types of hereditary spastic quadriplegia,
like those caused by PLP1 (MIM 312920), L1CAM (MIM(D) Immunoblot analysis of V5-tagged wild-type and mutated AP4M1 expressed in HEK293 cells, transfected with the wild-type, and
mutated AP4M1 cDNA. a-V5 as well as a-AP4M1_lupin antibodies visualized an expected protein band of 50 kDa from the wild-type
cDNA construct and a band of reduced size from the mutated construct. V5-tagged cDNA constructs of TSC2 gene (250 kDa) were trans-
fected separately and in combination with AP4M1 so that the system for transfection efﬁciency could be tested.
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307000), and MCT8 (MIM 300523) mutations, are easily
differentiated by their X-linked inheritance pattern and
speciﬁc signs (diffuse hypomyelination in PLP1, high-pres-
sure hydrocephalus in L1CAM, and extrapyramidal signs
in MCT8).
Glutamate excitotoxicity and abnormalities of AMPA
receptors are observed in hypoxy-ischemia models of cere-
bral palsy.12,13 AMPA receptors are widely expressed in
cerebral hemispheres. GluRd2 and AMPA receptors colocal-
ize to dendritic spines of rat cerebellum.42 Misrouting of
GluRd2 and AMPA receptors GluR1–GluR4 in brain of
knockout mice lacking the AP-4 b-subunit has recently
been shown, and this effect was reproduced by exclusive
downregulation of AP-4 m expression.16 Knockouts show
swelling of PC terminal axons and accumulation of LDLR
(MIM 606945), AMPA, and GluRd2 in autophagosomes at
or near the terminal ends of axons in the deep cerebellar
nuclei. Lack of GluR1–GluR4 immunorectivity of commer-
cial antibodies did not allow determination of receptor
routing in our proband IV-5; however, degeneration of
cerebellar dentate neurons in our patient might relate to
a similar mechanism.
Brain immunohistochemistry showed abnormal stain-
ing of glutamate receptor GluRd2 in the PC perikarya of
proband IV-5, suggesting abnormal vesicle-mediated trans-
port to the dendrites and retention at the trans-Golgi
network. Also, structural changes in dendritic arborization
of PC cells were observed. Abnormal dendritic arborization
is seen in many developmental disorders associated with
motor and cognitive abnormalities like Fragile X (MIM
300624) and Rett syndrome47,48 (MIM 312750). This indi-
cates that neuronal dysfunction is concomitant with the
apparent white matter loss on routine MRI; such a loss is
possibly a secondary phenomenon.
Yap et al.38 suggested that AP-4 interacts with GluRd2
and might be involved in glutamate trafﬁcking in the
dendritic spines of cerebellar PC. GluRd2 plays a crucial
role in motor coordination, PC synapse formation, and
induction of cerebellar long-term depression (LTD), a
form of synaptic plasticity underlying motor learning.
Hotfootmutations in mice consist of various deletions in
the GluRd2 gene and result in aberrant localization of the
mutant receptor, leading to profound motor disturbances.
The protein is not transported beyond the endoplasmic
reticulum (ER) or cis-Golgi apparatus.49 Similarly in our
proband IV-5, aberrant localization of GluRd2 has been
observed in the soma of Purkinje cells.
Cerebellum and cerebral white matter of proband IV-5
showed PC with abnormal dendritic arborization,
decreased amounts of synapses, and irregular thickened
axons. GluRd2 immunostaining suggested mislocalization
of the GluRd2 cargo protein to the perinuclear region of
Purkinje cells as well. The effect on cerebellar function of
impaired GluRd2 transport in general and in this family
in particular is unclear. Signs of cerebellar dysfunction
were difﬁcult to evaluate in our patients because of their
severe quadriplegia and mental retardation.50 The American Journal of Human Genetics 85, 40–52, July 10, 200It is possible that the AP4M1 mutation affects transport
of several glutamate receptors, also in cerebral hemi-
spheres. In all four known AP complexes, the m subunit is
essential for binding of cargo proteins, like several
membrane receptors.17,50
The AP4M1 gene encodes the m subunit of the adaptor
protein complex-4. The splice site mutation in CST
destroys the donor splice site of intron 14, and only aber-
rant AP4M1 mRNA is synthesized in the patients. The
mutant mRNA lacks exon 14 and has a premature stop
codon in exon 15 leading to truncation of the COOH
terminus, which is the site of cargo binding. The mutant
mRNA inHEK293 cells leads to the synthesis of an aberrant
protein. The mutation possibly causes impaired function
of the AP-4 complex without disassembly or degradation
of the whole complex. It is also possible that the mutated
m subunit functionally disables the whole AP-4 complex,
given that a large part of the C terminus, including exons
14 and 15, belongs to the Mu homology domain proﬁle
(Prosite database, entry PS51072), which is necessary for
cargo protein binding.51
Mutations in other adaptor-related complexes have been
related to human disease.19 Mutations in AP1S2 (MIM
300629), the sigma 2 subunit of the AP1 complex, which
is located on Xp22, are described in patients with mental
retardation, delayed motor development, hydrocephalus,
and basal ganglia calciﬁcations52,53 (MIM 300630). Com-
pound heterozygous mutations in the beta3A subunit of
the AP-3 protein (MIM 603401) complex have been
described in patients with Hermansky-Pudlak syndrome
type 2 (MIM 608233).54 These ﬁndings reveal the physio-
logical importance of uniquitous AP complexes in brain
function, but disease pathogenesis is not understood.
We have not been able to identify CST in a second pedi-
gree. We sequenced AP4M1 in six sporadic patients with
a comparable phenotype and no history of perinatal
injury, but no mutation was found. This suggests that
CST is a very rare disorder.
We hypothesize that AP4M1mutation causes a develop-
mental defect of the brain leading to congenital spastic
tetraplegia and mimicking glutamate-mediated perinatal
white matter injury through early neuroaxonal degenera-
tion and secondary white matter loss and that abnormal
cycling of glutamate receptors might be the underlying
pathogenic mechanism.
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